InvestorsObserver is giving CymaBay Therapeutics Inc (CBAY) an Analyst Rating Rank of 74, meaning CBAY is ranked higher by analysts than 74% of stocks. The average price target for CBAY is $11.25 and analyst’s rate the stock as a Strong Buy.
Wall Street analysts are rating CBAY a Strong Buy today. Find out what this means to you and get the rest of the rankings on CBAY!